Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.

[1]  P. Musto.  Thalidomide therapy in adult patients with myelodysplastic syndrome , 2006, Cancer.

[2]  H. Dombret,et al.  Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience. , 2006 .

[3]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[4]  S. Alberts,et al.  Thalidomide therapy in adult patients with myelodysplastic syndrome , 2006, Cancer.

[5]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[6]  L. Mannone,et al.  High‐dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study , 2006, British journal of haematology.

[7]  John M Bennett,et al.  Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.

[8]  P. Fenaux,et al.  A non‐randomised dose‐escalating phase II study of thalidomide for the treatment of patients with low‐risk myelodysplastic syndromes: the Thal‐SMD‐2000 trial of the Groupe Français des Myélodysplasies , 2005, British journal of haematology.

[9]  A. Stamatoullas,et al.  Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study. , 2005 .

[10]  A. Ganser,et al.  Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31–q33 with a combination of all-trans-retinoic acid and tocopherol-α: a phase II study , 2005, Annals of Hematology.

[11]  L. Rimsza,et al.  Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.

[12]  H. Dombret,et al.  Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. , 2004, Blood.

[13]  Robert B Howe,et al.  The WHO classification of MDS does make a difference. , 2004, Blood.

[14]  H. Deeg,et al.  Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes , 2003, British journal of haematology.

[15]  U. Germing,et al.  Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome , 2003, Leukemia.

[16]  Nikolaos Laoutaris,et al.  Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients , 2002, British journal of haematology.

[17]  P. Venugopal,et al.  Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. , 2001, Blood.

[18]  M. Lübbert,et al.  Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine , 2001, British journal of haematology.

[19]  B. Cheson,et al.  Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.

[20]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  I. Dybedal,et al.  Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. , 1998, Blood.

[22]  L. Michaux,et al.  5q-, twenty-five years later: a synopsis. , 1997, Cancer genetics and cytogenetics.

[23]  F. Gardner,et al.  Low‐dose ARA‐C consistently induces hematologic responses in the clinical 5q–syndrome , 1994, American journal of hematology.

[24]  N. Gattermann,et al.  All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. , 1993, Blood.

[25]  P. Greenberg,et al.  Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. , 1993, Blood.

[26]  G. Tricot,et al.  The 5q-anomaly. , 1985, Cancer genetics and cytogenetics.